Announcements Trials
Browse Landscape

Phase

Phase 2 41Phase 3 29Phase 1 18Phase 1/2 10Phase 2/3 2Phase 4 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 2

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Topotecan × Thoracic × Clear all
NCT07106528 2025-08-06

Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer

Peking Union Medical College Hospital

Phase 2/3 Not yet recruiting
128 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

United Therapeutics

Phase 2/3 Completed
483 enrolled 19 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡